Research Analysts Offer Predictions for BCRX Q1 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at Wedbush issued their Q1 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, February 25th. Wedbush analyst L. Chico forecasts that the biotechnology company will earn ($0.06) per share for the quarter. Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.15 EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $0.69 EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.09 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The company’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS.

BCRX has been the topic of several other research reports. Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Needham & Company LLC increased their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Trading Up 1.0 %

NASDAQ BCRX opened at $8.36 on Thursday. The stock has a fifty day simple moving average of $8.07 and a 200-day simple moving average of $7.85. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.50. The stock has a market cap of $1.73 billion, a PE ratio of -13.70 and a beta of 1.75.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Counterweight Ventures LLC grew its stake in BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after buying an additional 79,884 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after buying an additional 86,571 shares during the last quarter. Principal Financial Group Inc. grew its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after buying an additional 481,359 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.